Off-the-Shelf immune cell therapy tested for tough lymphoma cases
Disease control
Terminated
This early-stage study tested the safety and initial effectiveness of ATA3219, a new type of 'off-the-shelf' immune cell therapy, for adults with B-cell non-Hodgkin lymphoma that has returned or not responded to prior treatments. The therapy involves collecting and modifying a do…
Phase: PHASE1 • Sponsor: Atara Biotherapeutics • Aim: Disease control
Last updated Mar 31, 2026 12:10 UTC